Epilepsies, Partial
Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)
Subtype terms (6)
More specific conditions that are subtypes of Epilepsies, Partial in the MeSH hierarchy.
- Epilepsy, Complex Partial
10 drugs (8 approved, 2 experimental)
- Epilepsy, Frontal Lobe
- Epilepsy, Partial, Motor
1 drug experimental
- Epilepsy, Partial, Sensory
2 drugs (1 approved, 1 experimental)
- Epilepsy, Rolandic
4 drugs (3 approved, 1 experimental)
- Epilepsy, Temporal Lobe
5 drugs (3 approved, 2 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (10)
Phase 3 trials (7)
Phase 2 trials (12)
Phase 1 trials (4)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (23)
- Eisai
- Pfizer
- Novartis
- Yung Shin Pharm. Ind. Co., Ltd.
- National Cancer Institute (NCI)
- Azienda Ospedaliera San Gerardo di Monza
- Hoosier Cancer Research Network
- Northeast Regional Epilepsy Group
- Seoul National University
- University of Rochester
- University of Salzburg
- Yonsei University
- Mayo Clinic
- Taichung Veterans General Hospital
- Mid-Atlantic Epilepsy and Sleep Center
- Konkuk University
- Mario Negri Institute
- Swiss Epilepy Centre
- Johannes Gutenburg University
- Lundbeck
- Keimyung University
- Johnson and Johnson
- Government of Italy
Organization Involved with Phase 3 Indications (16)
- Abbott
- FGK Clinical Research GmbH
- GlaxoSmithKline
- Parexel
- Arvelle
- Sunovion
- Valexfarm
- Desitin Arzneimittel GmbH
- Cancer Research Network
- Emory University
- Supernus Pharmaceuticals
- Friedrich Wilhelms University
- National Institute of Psychiatry and Neurology, Budapest, Hungary
- Hospital Ruber Internacional
- Hospital Santo António Largo, Porto, Portugal
- Bial
Organization Involved with Phase 2 Indications (14)
- Vertex
- Biogen
- Baxalta
- Cerebral Therapeutics LLC
- Marinus Pharmaceuticals
- Xenon Pharmaceuticals Inc.
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Oregon Health and Science University
- University of Calgary
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Western Ontario
- NCGS, Inc.
- Oregon's Wild Harvest
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (7)